Saturday, June 10, 2017

Mass. General study finds potential mechanism for BCG vaccine reversal of type 1 diabetes

Data presented at American Diabetes Association meeting describes increase in immune cells that control autoimmunity

New data from an FDA-approved clinical trial testing the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes are being presented at the 75th Scientific Sessions of the American Diabetes Association. The data demonstrate a potential new mechanism by which the BCG vaccine may restore the proper immune response to the insulin-secreting islet cells of the pancreas. Presented by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital Immunobiology Laboratory and principal investigator of the trial, the findings suggest that BCG may induce a permanent increase in expression of genes that restore the beneficial regulatory T cells (Tregs) that prevent the immune system from attacking the body’s own tissue. The results are being presented at 10:30 am Pacific time on Saturday, June 10.

“Many groups are looking at the ability of BCG vaccination to reverse autoimmunity,” says Faustman, who is an associate professor of Medicine at Harvard Medical School. “We and other global efforts have known for some time that restoring beneficial Treg cells might halt the abnormal self-reactivity in type 1 diabetes and other autoimmune diseases, but therapies to restore this immune balance have not achieved long-lasting results. The discovery that BCG restores Tregs through epigenetics – a process that modulates whether or not genes are expressed – is exciting. This now provides a better idea of how BCG vaccination appears to work by powerfully modulating Treg induction and resetting the immune system to halt the underlying cause of the disease.”

Type 1 diabetes is an autoimmune disease characterized by the destruction of islets by autoreactive T cells, which mistakenly attack islets as if they were an infection. Tregs are the immune system’s “brakes” that normally prevent misdirected attacks against tissues without dampening the entire system. Several research groups have suggested methods for introducing or expanding Tregs in patients with type 1 diabetes, but to date no therapies have been approved.

Best known for its role in tuberculosis prevention, the BCG vaccine is based on a harmless strain of bacteria related the one that causes tuberculosis. A generic drug with over 100 years of clinical use and safety data, BCG is currently approved by the FDA for vaccination against tuberculosis and for the treatment of bladder cancer. Multiple international studies are currently investigating the potential of repeat BCG vaccinations to prevent and reverse autoimmune diseases including type 1 diabetes and multiple sclerosis.

“BCG is interesting because it brings into play so many areas of immunology that we as a community have been looking at for decades, including Tregs and the hygiene hypothesis,” says Faustman. “Repeat BCG vaccination appears to permanently turn on signature Treg genes, and the vaccine’s beneficial effect on host immune response recapitulates decades of human co-evolution with myocbacteria, a relationship that has been lost with modern eating and living habits. It is incredible that a safe and inexpensive vaccine may be the key to stopping these terrible diseases.”

Faustman’s research team was the first group to document reversal of advanced type 1 diabetes in mice and subsequently completed a successful phase I human clinical trial of BCG vaccination. The five-year, 150-person, phase II trial is investigating whether repeat BCG vaccination can clinically improve type 1 diabetes in adults with existing disease and is almost fully enrolled. Details on the trial and enrollment are available here.

Long-term follow-up data from the phase I trial will be published later this year. The phase II trial is entirely funded by private philanthropy from individuals and family foundations. Additional information about the clinical trial, including information for potential participants and financial supporters, is available at the Faustman Lab website or by emailing DiabetesTrial@partners.org.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America’s Best Hospitals.

Media contact: Terri Ogan, togan@partners.org, 617 726-0954

Browse the Entire Newsroom Archive

Back to Top